Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers

被引:0
作者
Zuo, Chun-Jian [1 ]
Tian, Jie [2 ,3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, 1 Youyi Rd, Chongqing 400010, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
关键词
Lung cancer; apoptosis; immunotherapy; bibliometric analysis; research trends; CELL-DEATH; T-CELLS; INHIBITORS; RESISTANT; THERAPY; CHEMOTHERAPY; NIVOLUMAB; MECHANISM; EFFICACY; BLOCKADE;
D O I
10.1080/21645515.2025.2488074
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Apoptosis is vital for improving the efficacy of lung cancer (LC) immunotherapy by targeting cancer cell elimination. Despite its importance, there is a lack of comprehensive bibliometric studies analyzing global research on apoptosis in LC immunotherapy. This analysis aims to address this gap by highlighting key trends, contributors, and future directions. A total of 969 publications from 1996 to 2024 were extracted from the Web of Science Core Collection. Analysis was conducted using VOSviewer, CiteSpace, and the R package 'bibliometrix.' The study included contributions from 6,894 researchers across 1,469 institutions in 61 countries, with research published in 356 journals. The volume of publications has steadily increased, led by China and the United States, with Sichuan University as the top contributor. The journal Cancers published the most articles, while Cancer Research had the highest co-citations. Yu-Quan Wei was the leading author, and Jemal, A. was the most frequently co-cited. Key research themes include "cell death mechanisms," "immune regulation," "combination therapies," "gene and nanomedicine applications," and "traditional Chinese medicine (TCM)." Future research is likely to focus on "coordinated regulation of multiple cell death pathways," "modulation of the tumor immune microenvironment," "optimization of combination therapies," "novel strategies in gene regulation," and the "integration of TCM" for personalized treatment. This is the first bibliometric analysis on the role of apoptosis in LC immunotherapy, providing an landscape of global research patterns and emerging therapeutic strategies. The findings offer insights to guide future research and optimize treatment approaches.
引用
收藏
页数:22
相关论文
共 137 条
  • [1] Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
    Ali, Saira R.
    Humphreys, Karen J.
    McKinnon, Ross A.
    Michael, Michael Z.
    [J]. DRUG DEVELOPMENT RESEARCH, 2015, 76 (06) : 296 - 317
  • [2] Emerging role of immunogenic cell death in cancer immunotherapy
    Arimoto, Kei-ichiro
    Miyauchi, Sayuri
    Liu, Mengdan
    Zhang, Dong-Er
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
    Ashkenazi, Avi
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (02) : 487 - 489
  • [4] Design of a nanozyme-based magnetic nanoplatform to enhance photodynamic therapy and immunotherapy
    Bai, Chen
    Liu, Jiajing
    Bai, Luyao
    Yao, Dapeng
    Li, Xiaofeng
    Zhang, Haoran
    Guo, Dong
    [J]. JOURNAL OF PHARMACEUTICAL ANALYSIS, 2024, 14 (09)
  • [5] Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: Trends, collaborations, and future directions
    Bai, Heng
    Tian, Jie
    [J]. AUTOIMMUNITY REVIEWS, 2025, 24 (01)
  • [6] Advancing the understanding of autoimmune/inflammatory syndrome induced by adjuvants (ASIA): Global research trends, key themes, and emerging frontiers
    Bai, Heng
    Tian, Jie
    [J]. AUTOIMMUNITY REVIEWS, 2025, 24 (01)
  • [7] Enhancing dendritic cells by inhibiting BCL2
    Booth, Christopher A. G.
    Lane, Andrew A.
    [J]. TRENDS IN CANCER, 2023, 9 (12) : 987 - 988
  • [8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [9] MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
    Braegelmann, Johannes
    Lorenz, Carina
    Borchmann, Sven
    Nishii, Kazuya
    Wegner, Julia
    Meder, Lydia
    Ostendorp, Jenny
    Ast, David F.
    Heimsoeth, Alena
    Nakasuka, Takamasa
    Hirabae, Atsuko
    Okawa, Sachi
    Dammert, Marcel A.
    Plenker, Dennis
    Klein, Sebastian
    Lohneis, Philipp
    Gu, Jianing
    Godfrey, Laura K.
    Forster, Jan
    Trajkovic-Arsic, Marija
    Zillinger, Thomas
    Haarmann, Mareike
    Quaas, Alexander
    Lennartz, Stefanie
    Schmiel, Marcel
    D'Rozario, Joshua
    Thomas, Emily S.
    Li, Henry
    Schmitt, Clemens A.
    George, Julie
    Thomas, Roman K.
    von Karstedt, Silvia
    Hartmann, Gunther
    Buettner, Reinhard
    Ullrich, Roland T.
    Siveke, Jens T.
    Ohashi, Kadoaki
    Schlee, Martin
    Sos, Martin L.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [10] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Bernabe Caro, Reyes
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Pluzanski, Adam
    Burgers, Jacobus
    Mahave, Mauricio
    Ahmed, Samreen
    Schoenfeld, Adam J.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura J.
    Ramalingam, Suresh S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1200 - +